A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
Clinical trial NCT07719855 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07719855
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2030-07-01
- Enrollment
- 652
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.